)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ganga Pharmaceuticals
Ganga Pharmaceuticals (539680) investor relations material
Ganga Pharmaceuticals H1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 26/27 earnings summary2 Nov, 2026
Executive summary
Unaudited H1 results for the half year ended September 30, 2026, were approved by the Board on November 2, 2026; auditors issued a limited review report.
Financial highlights
Revenue from operations was Rs 141.63 lakh versus Rs 136.65 lakh in H1 FY25; total income was Rs 155.27 lakh.
Profit before tax was Rs 2.52 lakh versus Rs 3.35 lakh in H1 FY25; total expenses were Rs 152.76 lakh versus Rs 144.16 lakh.
Net profit was Rs 1.86 lakh versus Rs 5.50 lakh in H1 FY25; other income was Rs 13.64 lakh versus Rs 14.80 lakh.
Segment performance
Operations were in one business segment: Ayurveda; segment information was therefore not required under AS 17.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ganga Pharmaceuticals
- Profit rose as revenue stayed nearly flat; IPO funding supported the core Ayurveda business.539680
H2 15/16 - FY17 profit rose as Ayurveda product development and distribution remained central priorities.539680H2 16/17
- Revenue and profit improved as Ayurvedic product and distribution expansion remained central.539680H2 18/19
- FY18 profit rose as Ayurveda product and distribution plans advanced amid industry risks.539680H2 17/18
- Revenue declined, but profit edged up as COVID-19 disrupted FY20 operations.539680H2 19/20
- Pandemic disruption cut revenue and earnings as Ayurveda-focused growth plans advanced.539680H2 20/21
- Revenue and profit rose in FY22 despite macro headwinds; no dividend was recommended.539680H2 21/22
- FY23 income and profit edged higher as Ayurveda growth plans met industry and macro risks.539680H2 22/23
- FY26 revenue and profit rose, equity increased, and auditors gave an unmodified opinion.539680H2 25/26
Next Ganga Pharmaceuticals earnings date
H2 26/2720 May, 2027
Ganga Pharmaceuticals
Next Ganga Pharmaceuticals earnings date
H2 26/2720 May, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ganga Pharmaceuticals Limited is a pharmaceutical company engaged in the manufacturing and marketing of Ayurvedic medicines and herbal healthcare products. The company produces a variety of traditional formulations in the form of tablets, powders, syrups, and oils, catering to multiple therapeutic areas such as digestion, immunity, and general wellness. It distributes its products through domestic retail channels and may also serve export markets. Ganga Pharmaceuticals Limited operates in accordance with Ayurvedic principles and regulatory standards. The company is headquartered in Thane, India, and its shares are listed on the BSE.